STTR Phase I: A Novel Tissue-Engineered Platform for Cancer Modeling and Drug Screening — NSF Award to VIVOSPHERE LLC (AL, $275,00
The broader impact of this Small Business Technology Transfer Phase I project lies primarily in providing more effective drug screening models to eliminate ineffective drug candidates at an early stage. This may expedite the anti-cancer drug development process and reduce excessive expenses during clinical trials, whic
| Award title | STTR Phase I: A Novel Tissue-Engineered Platform for Cancer Modeling and Drug Screening |
|---|---|
| Award ID | 2432785 |
| Awardee | VIVOSPHERE LLC |
| City | AUBURN |
| State | AL |
| Amount obligated | $275,000 |
| Principal investigator | Yuan Tian |
| Program | STTR Phase I |
| Start date | 05/01/2025 |
| Abstract | The broader impact of this Small Business Technology Transfer Phase I project lies primarily in providing more effective drug screening models to eliminate ineffective drug candidates at an early stage. This may expedite the anti-cancer drug development process and reduce excessive expenses during clinical trials, which may increase the R&D returns for pharmaceutical companies and reduce healthcare costs for the customers. Furthermore, the sooner that an efficacious anti-cancer drug can be broug |
| Source | NSF Awards |
$799/mo
Try NSFGrants →